Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Gastroparesis Drugs Market

Gastroparesis Drugs Market – By Drug Class (Prokinetic Agents, Proton Pump Inhibitor), Disease Type (Idiopathic Gastroparesis), Route of Administration (Oral, Injectable), Drug Type (OTC, Prescription), Distribution Channel (Retail Pharmacies, Online) – Global Forecast (2024 – 2032)

  • Report ID: GMI9322
  • Published Date: May 2024
  • Report Format: PDF

Gastroparesis Drugs Market Size

Gastroparesis Drugs Market size was valued at USD 5.9 billion in 2023 and is growing at a CAGR of 5% between 2024 and 2032, driven by factors such increased prevalence of diabetes worldwide due to rapid urbanization, lifestyles, and rising rates of regular alcohol and tobacco consumption.

Gastroparesis Drugs Market

For instance, as per the article published by Multidisciplinary Digital Publishing Institute (MDPI) in February 2024, it was found that approximately 9.3% of individuals with diabetes may experience the onset of gastroparesis during their illness. This risk appears to be heightened in individuals with long-standing type 1 diabetes or type 2 diabetes lasting ten years or more. Thus, the rapid increase in the prevalence of diabetes globally is expected to increase the incidence of diabetic gastroparesis that propel the demand for gastroparesis drugs, thereby boosting the growth of the market. Furthermore, the introduction of innovative drugs, by the manufacturers, aimed at symptom management, particularly for nausea and vomiting, is an important driving factor.

Gastroparesis means stomach paralysis - it is a condition affecting the nerves and muscles in the stomach. It interferes with the muscle activity (peristalsis) that moves food through the stomach and into the small intestine. Gastroparesis drugs are medications used to manage the symptoms of gastroparesis; a condition characterized by delayed emptying of the stomach. These medications aim to improve gastric motility and alleviate symptoms such as nausea, vomiting, bloating, and abdominal pain.

Gastroparesis Drugs Market Trends

  • The demand for the treatment of gastroparesis fuels research and development activities in the pharmaceutical industry, leading to the introduction of new drugs tailored to address the symptoms and underlying causes of gastroparesis. For instance, as per an article published in National Institute of Health in August 2022, it has been reported that prevalence of gastroparesis is 267.7 per 100,000 adults in the U.S. However, a population?based estimate suggests that up to 1.8% of the population is affected. Therefore, as awareness about gastroparesis improves among healthcare professionals and patients, there is greater diagnosis and treatment-seeking behavior, further propelling the demand for gastroparesis drugs.

Gastroparesis Drugs Market Analysis

Gastroparesis Drugs Market, By Drug Class, 2021 – 2032 (USD Billion)

Based on the drug class, the global market is classified into prokinetic agents, antiemetic agents, proton pump inhibitors and other drug classes. The proton pump inhibitors segment dominated the market with revenue of USD 2.1 billion in 2023.

  • Gastroparesis is more common among older adults, and as the global population ages, there's a corresponding increase in the incidence of gastroparesis. Therefore, the increase in the number of research and development activities aimed at improving drug delivery systems for proton pump inhibitors may lead to the development of more effective and convenient formulations. For instance, long-acting or sustained-release formulations may improve patient compliance and treatment outcomes. Thus, availability of wide range of drugs in the market will drive the market growth.


Gastroparesis Drugs Market, By Disease Type (2023)

Based on the disease type, the global gastroparesis drugs market is classified into diabetes gastroparesis, idiopathic gastroparesis, and post-surgical gastroparesis. The diabetes gastroparesis segment dominated the market with market share of 44.6% in 2023.

  • As diabetic rates continue to rise globally, particularly with lifestyle changes and aging populations, the prevalence of gastroparesis is also expected to increase. This surge in diabetic gastroparesis cases creates a growing demand for effective treatments to manage symptoms and improved patients' outcome. Thus, the market offering new therapeutic options to address the unmet medical needs of individuals suffering from this debilitating condition.

Based on route of administration, the gastroparesis drugs market is classified into oral, injectable, and other routes of administration. Oral segment is expected to reach 4.8 billion by 2032.

  • Oral medications offer a convenient and non-invasive treatment option, catering to the preference of many patients over invasive procedures or injections. Also, advancements in drug development have led to the introduction of more effective oral medications with fewer side effects, further fueling the demand.
  • Further, several patients prefer oral dosage form over alternative routes like parenteral due to convenience and ease of administration, which can drive the demand for oral products, thereby supplementing the market growth.

Based on drug type, the gastroparesis drugs market is classified into OTC drug and prescription drugs. OTC drugs segment dominated the market with market share of 64.1% in 2023.

  • With an increasing number of individuals experiencing gastroparesis, there's a rising interest in OTC remedies offering relief. These drugs typically target symptoms rather than the underlying cause, providing quick relief for milder cases or as adjunctive therapy alongside prescription medications.
  • In addition, the accessibility and convenience of OTC options appeal to consumers seeking immediate relief without the need for a prescription or healthcare provider visit are the major factors that boost the growth of the market.

Based on distribution channel, the gastroparesis drugs market is classified into hospital pharmacies, retail pharmacies and online pharmacies. Retail pharmacies segment is expected to exhibit 5.2% CAGR between 2024 - 2032.

  • Retail pharmacies serve as key distribution points for these medications, ensuring patients have timely access to the drugs they need. Additionally, retail pharmacies provide essential patient education and support, helping individuals understand their treatment regimens.
  • Moreover, through their widespread presence in communities and availability of different medication including OTC drugs, retail pharmacies effectively reach a large patient population, thereby contributing significantly to the market growth.


North America Gastroparesis Drugs Market, 2021 – 2032 (USD Billion)

The gastroparesis drugs market in U.S. is expected to reach USD 3.5 billion by end of 2032.

  • The increasing prevalence of gastroparesis in the region, often associated with conditions such as diabetes and neurological disorders, has heightened the demand for effective treatment options.
  • Additionally, advancements in healthcare infrastructure and rising awareness about the condition among both patients and healthcare professionals have contributed to greater diagnosis and treatment-seeking behavior, further fueling market growth.
  • Moreover, ongoing research and development activities aimed at introducing novel therapeutic agents with improved efficacy and safety profiles are expected to expand the market further.

Germany to experience the highest growth rate in the market, outstripping other countries in Europe in the assessment period.

  • Growing acute gastrointestinal illness in adults in country is expected to spur the product adoption. For instance, according to Cambridge University Press & Assessment report 2018, nearly 23 percent of those aged 65 years and over were diagnosed with a gastrointestinal condition. Hence, a well-developed healthcare infrastructure with advanced medical facilities and specialized centers for gastrointestinal disorders will augment the market growth.
  • Further, improved access to healthcare services, including diagnosis and treatment for gastroparesis stimulates the demand for gastroparesis drugs, thereby driving the market growth.

The India gastroparesis drugs market is expected to grow with a significant CAGR during the forecast period.

  • Urbanization and the adoption of western lifestyles in India contribute to changes in dietary habits, including the consumption of processed foods which are high in fat and sugar. These dietary changes can increase the risk of developing gastrointestinal disorders like gastroparesis, thereby driving the demand for medications to manage symptoms.

Gastroparesis Drugs Market Share

The competitive landscape of the gastroparesis drugs industry is characterized by the presence of established pharmaceutical companies that manufacture drugs used for gastroparesis vying for market share. Key players are engaging in strategic initiatives such as new product launch, acquisitions, investment, and partnerships to strengthen their product portfolio. Companies are actively adopting a multi-pronged approaches to address the rising demand for effective gastroparesis drugs.

Gastroparesis Drugs Market Companies

Prominent players operating in the gastroparesis drugs industry are as mentioned below:

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Ltd.
  • Evoke Pharma
  • Pfizer Inc.
  • Salix Pharmaceuticals
  • Takeda Pharmaceutical, Inc.
  • Teva Pharmaceutical Inc.

Gastroparesis Drugs Industry News:

  • In December 2023, Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis. This strategy is expected to spur company’s product pipeline and offerings.
  • In June 2020, Evoke Pharma, Inc. a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for GIMOTI (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. This strategy enabled company to add value to its existing product portfolio.

The gastroparesis drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

  • Prokinetic agents
  • Antiemetic drugs
  • Proton pump inhibitors
  • Other drug classes

Market, By Disease Type

  • Diabetes gastroparesis
  • Idiopathic gastroparesis
  • Post-surgical gastroparesis

Market, By Route of Administration

  • Oral
  • Injectables
  • Other routes of administration

Market, By Drug Type

  • OTC drugs
  • Prescription drugs

Market, By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • The Netherlands
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • South Africa
    • Saudia Arabia
    • UAE
    • Rest of Middle East and Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gastroparesis drugs industry size was USD 5.9 billion in 2023 and will depict a 5% CAGR from 2024 to 2032 due to the increasing prevalence of gastroparesis globally, particularly among diabetic patients, rising awareness about the condition, and advancements in diagnostic techniques.

The diabetes gastroparesis segment captured 44.6% of the market share in 2023, driven by the escalating prevalence of diabetes worldwide coupled with the consequential rise in gastroparesis cases among diabetic patients.

North America gastroparesis drugs industry will record USD 3.5 billion by 2032, attributed to advanced healthcare infrastructure, high awareness about gastroparesis, and robust R&D activities.

Key gastroparesis drug firms are Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Evoke Pharma, Pfizer Inc., Salix Pharmaceuticals, Takeda Pharmaceutical, Inc., and Teva Pharmaceutical Inc., among others.

Gastroparesis Drugs Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 298
  • Countries covered: 22
  • Pages: 182
 Download Free Sample